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Abstract
Background: The molecular mechanisms of the development and progression of bladder cancer are poorly
understood. The objective of this study was to analyze the expression of Bmi-1 protein and its clinical significance
in human bladder cancer.
Methods: We examined the expression of Bmi-1 mRNA and Bmi-1 protein by RT-PCR and Western blot,
respectively in 14 paired bladder cancers and the adjacent normal tissues. The expression of Bmi-1 protein in 137
specimens of bladder cancer and 30 specimens of adjacent normal bladder tissue was determined by
immunohistochemistry. Statistical analyses were applied to test the relationship between expression of Bmi-1, and
clinicopathologic features and prognosis.
Results: Expression of Bmi-1 mRNA and protein was higher in bladder cancers than in the adjacent normal
tissues in 14 paired samples (P < 0.01). By immunohistochemical examination, five of 30 adjacent normal bladder
specimens (16.7%) versus 75 of 137 bladder cancers (54.3%) showed Bmi-1 protein expression (P < 0.05). Bmi-1
protein expression was intense in 20.6%, 54.3%, and 78.8% of tumors of histopathological stages G1, G2, and G3,
respectively (P < 0.05). Expression of Bmi-1 protein was greater in invasive bladder cancers than in superficial
bladder cancers (81.5% versus 32.5%, P < 0.05). In invasive bladder cancers, the expression of Bmi-1 protein in
progression-free cancers was similar to that of cancers that have progressed (80.0% versus 82.4%, P > 0.5). In
superficial bladder cancers, the expression of Bmi-1 protein in recurrent cases was higher than in recurrence-free
cases (62.5% versus 13.7%, P < 0.05). Bmi-1 expression was positively correlated with tumor classification and
TNM stage (P < 0.05), but not with tumor number (P > 0.05). Five-year survival in the group with higher Bmi-1
expression was 50.8%, while it was 78.5% in the group with lower Bmi-1 expression (P < 0.05). Patients with
higher Bmi-1 expression had shorter survival time, whereas patients with lower Bmi-1 expression had longer
survival time (P < 0.05).
Conclusion: Expression of Bmi-1 was greater in bladder cancers than in the adjacent normal tissues. The
examination of Bmi-1 protein expression is potentially valuable in prognostic evaluation of bladder cancer.
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Background
Bladder cancer is one of the most lethal urological malig-
nant tumors worldwide[1]. Although the treatment of
bladder cancer has improved greatly in recent years, the
incidence of this disease is gradually increasing [2]. More
than half of the patients with bladder cancer have
advanced stage disease with very poor prognosis[3].
Although some environmental factors and genetic factors
have been associated with bladder cancer [4-6], the
molecular mechanisms involved in the initiation and pro-
gression of bladder cancers remain unclear.
The  BMI1  gene was first isolated as an oncogene that
cooperated with c-Myc in generating lymphomas in a
murine model[7,8]. It is a transcriptional repressor
belonging to the Polycomb-group (PcG) family of pro-
teins involved in axial patterning, hematopoiesis, regula-
tion of proliferation, and senescence [9-11]. The BMI1
gene also was reported to immortalize bone marrow stro-
mal cells and cementoblast progenitor cells, albeit in com-
bination with other oncogenes [12,13]. In addition, the
BMI1 gene plays an important role in cell proliferation
and tumor progression [14-18]. The BMI1 gene is widely
expressed in diverse human tumors, including lympho-
mas, non-small cell lung cancer, B-cell non-Hodgkin's
lymphoma, breast cancer, colorectal cancer, and neurob-
lastoma [14-21], and has been shown to be a useful prog-
nostic marker in myelodysplastic syndrome and many
cancers, including nasopharyngeal carcinoma and gastric
cancer [14-21].
However, there is no published report on the expression
of Bmi-1 in bladder cancer. In this study we aimed to
explore the expression of Bmi-1 protein and its clinical
significance in human bladder cancers.
Methods
Patients and tissue specimens
For RT-PCR and Western blot analysis, we collected 14
paired transitional cell bladder cancers and adjacent nor-
mal tissues from the patients who underwent surgery
between March 2008 and April 2008. In addition, 137
paraffin-embedded samples of transitional cell bladder
cancer and 30 specimens of adjacent normal bladder tis-
sue were collected between 2000 and 2003 for immuno-
histochemical assay. All tumors were histologically and
clinically diagnosed by the cancer center of Sun Yat-sen
University. For the use of these clinical materials, prior
patient consent, and approval from the institute research
ethics committee (Approval number: YP2008063) were
obtained.
The disease stage of each patient was classified or reclassi-
fied according to the 2002 AJCC staging system[22]. The
137 patients included 115 males and 22 females from 14
to 72 years (mean, 56 years). Of these patients, 41 patients
underwent radical cystectomy, 20 patients underwent par-
tial cystectomy, and 76 patients underwent TURBT
(transurethral resection of bladder tumor). After partial
cystectomy and TURBT, mitomycin C was used in intra-
vesical therapy as weekly intravesical injection beginning
within 24 hours after surgery. Thirty specimens of adja-
cent normal bladder tissue distant from the tumor were
included for these patients, as well. The median follow-up
time for overall survival was 56 months for patients still
alive at the time of analysis, ranging from 11 to 86
months.
Reverse transcription – PCR analysis
Total mRNA was purified using TRIzol Reagent (Invitro-
gen, Carlsbad, CA, USA), and 1 μg of each sample was
reverse transcribed using TIAN Script Kit (TIANGEN, Bei-
jing, China). The BMI1 sense primer was 5'AGCAGAAAT-
GCATCGAACAA-3', and the antisense primer was
5'CCTAACCAGATGAAGTTGCTGA-3'. For the β-actin
gene, the sense primer was 5'CCCCTGGCCAAGGTCATC-
CATGACAACTTT-3', and the antisense primer was
5'GGCCATGAGGTCCACCACCCTGTTGCTGTA-3'. PCR
reactions were performed following the cycling parame-
ters on a PTC-200 PCR system (Bio-Rad, Hercules, Calif):
10 min at 94° followed by 28 cycles of 1 min at 94°, 1
min at 55°, 1 min at 72°, and a final cycle at 72°C for 10
min. PCR products were scanned, and quantification was
performed by the Quantity One program (Bio-Rad, Her-
cules, CA).
Western blot analysis
Total proteins were extracted with 1× SDS sample buffer
[62.5 mmol/L Tris-HCl (pH 6.8), 2% SDS, 10% glycerol,
and 5% 2-mercaptoethanol], and 30 μg of each protein
was electrophoretically separated in 12% SDS polyacryla-
mide gels, and transferred to polyvinylidene difluoride
membranes (Millipore). Rabbit polyclonal anti-Bmi-1
(1:800, Upstate Biotechnology, Lake Placid, NY) and anti-
Rabbit (1:2000, Santa Cruz Biotechnology, Santa Cruz,
CA) antibodies were used to detect Bmi-1 protein. Mouse
anti-α-tubulin (1:2000, Sigma) and anti-mouse (1:2000,
Santa Cruz Biotechnology, Santa Cruz, CA) antibodies
were used to detect α-tubulin. The Western blot bands
were scanned and were analyzed by the Quantity One
program (Bio-Rad, Hercules, CA).
Immunohistochemistry assay
Immunohistochemistry was performed to examine Bmi-1
expression in 137 human bladder cancers and 30 speci-
mens of adjacent normal bladder tissue. The procedures
were performed with classical protocols. In brief, paraffin-
embedded specimens were cut into 4-μm sections and
baked at 65° for 30 min. The sections were deparaffinized
with xylene and rehydrated. Sections were submerged intoBMC Cancer 2009, 9:61 http://www.biomedcentral.com/1471-2407/9/61
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EDTA antigenic retrieval buffer and microwaved for anti-
genic retrieval. The sections were then treated with 3%
hydrogen peroxide in methanol to quench the endog-
enous peroxidase activity, followed by incubation with
1% bovine serum albumin to block the nonspecific bind-
ing.
The Bmi-1 protein was detected using a mouse mono-
clonal antibody against Bmi-1 (Upstate Biotechnology,
Lake Placid, NY). The specimens were incubated with
anti-Bmi-1 antibody (1:100) overnight at 4°. In the nega-
tive control, primary antibody was replaced by the non-
immune mouse IgG of the same isotype. After washing,
the tissue sections were treated with biotinylated anti-
mouse secondary antibody followed by further incuba-
tion with a streptavidin-horseradish peroxidase complex.
The tissue sections were immersed in 3-amino-9-ethyl car-
bazole, and counterstained with 10% Mayer's hematoxy-
lin, dehydrated, and mounted in Crystal Mount.
The degree of immunostaining of formalin-fixed, paraf-
fin-embedded sections was reviewed and scored by two
independent observers. The proportion of cells expressing
Bmi-1 varied from 0% to 100%, and the intensity of
nuclear staining varied from weak to strong. Cells were
scored for intensity of staining on a scale of 0 (no stain-
ing), 1 (weak staining, light yellow), 2 (moderate staining,
yellowish brown), and 3 (strong staining, brown). Using
this method of assessment, we evaluated the expression of
Bmi-1 in bladder cancer tissue and in normal bladder tis-
sue. An optimal cutoff value was identified. An intensity
score of = 2 with at least 50% of malignant cells positive
for Bmi-1 staining was used to classify tumors with high
expression, and < 50% of malignant cells with nuclear
staining of intensity score of < 2 characterized tumors
with low expression of Bmi-1.
Statistical analysis
All statistical analyses were carried out with the SPSS 13.0
statistical software package. In the RT-PCR and Western
blot analysis, t-test was used to analyze the significance of
mRNA and protein expression between bladder cancers
and the adjacent normal tissues. We analyzed the relation-
ship between expression of Bmi-1 protein, clinicopatho-
logic features, and the clinical prognosis. The χ2 test for
proportion was used to analyze the relationship between
Bmi-1 expression and clinicopathologic characteristics.
Survival curves were plotted by the Kaplan-Meier method,
and compared by the log-rank test. We determined that
the assumption of proportional hazards was met in all
Cox regression models. The significance of various varia-
bles for survival was analyzed by the Cox proportional
hazards model in the multivariate analysis. P < 0.05 was
considered statistically significant.
Results
Expression of Bmi-1 mRNA and protein in paired bladder 
tissues
To ensure the reliability of this study, we first examined
the expression of Bmi-1 mRNA and Bmi-1 protein by RT-
PCR and Western blot, respectively in 14 bladder cancers.
The control samples were paired adjacent normal tissues
taken from the same patients. The relative level of Bmi-1
expression was compared in bladder cancers and the adja-
cent normal tissue (Figs. 1 and 2). The expression levels
were determined as a ratio between Bmi-1 and the refer-
ence protein (α-tubulin) or gene (β-actin) to correct for
variation in the quantity of protein and mRNA. In the RT-
PCR analysis, the ratios (bladder cancer/normal tissue)
were 4.97, 1.63, 1.37, 1.71, 1.09, 1.30, 2.19, 1.75, 2.05,
6.73, 1.28, 1.84, 12.67, and 1.42, respectively. In the
Western blot analysis, the ratios (bladder cancer/normal
tissue) were 10.71, 8.99, 6.05, 2.97, 2.55, 6.09, 35.47,
1.95, 2.12, 3.14, 7.42, 2.32, 5.46, and 32.47, respectively.
Expression of both mRNA and protein was found to be
higher in tumor tissues than in the paired adjacent normal
tissues (P < 0.01). Bmi-1 protein expression is up-regu-
Expression of Bmi-1 mRNA in paired bladder cancers and  the adjacent normal tissues by RT-PCR analysis Figure 1
Expression of Bmi-1 mRNA in paired bladder cancers 
and the adjacent normal tissues by RT-PCR analysis. 
A: RT-PCR analysis in 14 paired bladder cancers and the adja-
cent normal tissues (upper panel); β-actin as the internal con-
trol (showed in lower panel). B: The relative expression level 
of Bmi-1 in comparison to the expression level of β-actin.BMC Cancer 2009, 9:61 http://www.biomedcentral.com/1471-2407/9/61
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lated to a greater extent than is Bmi-1 mRNA expression in
cancer tissues relative to non-cancerous tissues.
Expression of Bmi-1 protein in paraffin-embedded bladder 
cancer samples
Expression and subcellular localization of Bmi-1 protein
were determined by immunohistochemistry in 137 paraf-
fin-embedded bladder cancer tissues, and 30 specimens of
adjacent normal bladder tissues. In non-cancerous tissues,
Bmi-1 protein staining was present in few cells, and the
protein staining was very weak (Fig. 3A, B). In tumor tis-
sues, specific Bmi-1 signals were localized mainly in the
nuclei of carcinoma cells in the form of yellow-brown
granules (Fig. 3C, D). Bmi-1 protein expression was high
in 54.3% of bladder cancers, while Bmi-1 expression was
observed in only 16.7% of adjacent normal tissues (P <
0.05).
Relationship between Bmi-1 protein expression and 
clinicopathological features
The relationship between the expression of Bmi-1 protein
and clinical characteristics is shown in Table 1. Intense
expression of Bmi-1 in bladder cancer was positively cor-
related with the histopathological classification, clinical
stage, and recurrence (P < 0.05); but was not correlated
with gender, age, or tumor number (P > 0.05). Intense
expression of Bmi-1 protein was noted in 20.6%, 54.3%,
and 78.8% of bladder tumors of histopathological grade
G1, G2, and G3, respectively (P < 0.05, χ2 test). Intense
Expression of Bmi-1 protein in paired bladder cancers and  the adjacent normal tissues by Western Blot analysis Figure 2
Expression of Bmi-1 protein in paired bladder can-
cers and the adjacent normal tissues by Western 
Blot analysis. A: Western Blot analysis in 14 paired bladder 
cancers and the adjacent normal tissues (upper panel); α-
tubulin as the loading control (showed in lower panel). B: 
The relative expression level of Bmi-1 in comparison to the 
expression level of α-tubulin.
Expression analysis of Bmi-1 protein by immunohistochemis- try Figure 3
Expression analysis of Bmi-1 protein by immunohis-
tochemistry. Bmi-1 staining was mainly localized within the 
nuclei, and it expressed was observed in cancer cell. A: Neg-
ative Bmi-1 staining in non-cancerous tissue (100×). B: Weak 
Bmi-1 staining in non-cancerous cells(400×). C: strong Bmi-1 
staining in tumor nests(400×). D: Strong nuclear stainingin 
most of the tumor cells (400×).
Table 1: Correlation between Bmi-1 expression and clinical-
pathologic features of the patient with bladder cancer
Bmi-1 expression P
Characteristics n Low High
Gender
Male 115 58 (50.4%) 57 (49.6%) 0.226
Female 22 8 (36.4%) 14 (63.6%)
Age
≤ 50 49 26 (53.1%) 23 (46.9%) 0.393
> 50 88 40 (45.5%) 48 (54.5%)
Tumor number
≤ 3 91 47 (51.6%) 44 (48.4%) 0.255
> 3 46 19 (41.3%) 27 (58.7%)
Histological grade
G1 34 27 (79.4%) 7 (20.6%) 0.001
G2 70 32 (45.7%) 38 (54.3%)
G3 33 7 (21.2%) 26 (78.8%)
Clinical stage
Ta, T1 83 56 (67.5%) 27 (32.5%) 0.001
T2, T3, T4 54 10 (18.5%) 44 (81.5%)
Superficial cancer
No recurrence 51 44 (86.3%) 7 (13.7%) 0.001
Recurrence 32 12 (37.5%) 20 (62.5%)BMC Cancer 2009, 9:61 http://www.biomedcentral.com/1471-2407/9/61
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expression of Bmi-1 protein was noted in 81.5% of inva-
sive bladder cancer and 32.5% of superficial bladder can-
cer (P < 0.05). In invasive bladder cancers, expression of
Bmi-1 protein in progression-free cancers was similar to
that of cancers with progression (80.0% versus 82.4%, P >
0.5). In superficial bladder cancers, Bmi-1 protein was
highly expressed in 62.5% in recurrent cases versus 13.7%
of recurrence-free cases (P < 0.05).
Survival analysis
Kaplan-Meier analysis and the log-rank test were used to
calculate the effect of the Bmi-1 expression on survival.
The five-year survival in the group of higher Bmi-1 expres-
sion was 50.8%, but it was 79.0% in the group of lower
Bmi-1 expression. The log-rank test showed that survival
was significantly different between these two groups (P =
0.0197). The expression level of Bmi-1 protein in bladder
cancer was significantly correlated with patient survival (P
< 0.001), and the correlation coefficient was -0.27, indi-
cating that a higher level of Bmi-1 expression was corre-
lated with shorter survival time. The low Bmi-1 expression
group had longer survival, whereas the high Bmi-1 expres-
sion group had shorter survival (Fig. 4). In addition, we
did multivariate survival analysis, which included Bmi-1
expression level, histological classification, and clinical
stage to test the independent effects of Bmi-1 on survival.
We found that Bmi-1 expression, histological classifica-
tion, and clinical stage were independent predictors of
survival (Table 2). Thus, our findings indicate that the
Bmi-1 protein expression level has a significant correla-
tion with clinicopathological features, and is a potential
prognostic marker for bladder cancer.
Discussion
At present, the molecular mechanisms of the initiation
and progression of bladder cancers are unclear, although
many genetic factors have been found to be associated
with bladder cancer [4-6]. In this study, we report that
Bmi-1 is overexpressed in human bladder cancers. The
overexpression of Bmi-1 protein was correlated with
tumor classification, recurrence, TNM stage, and progno-
sis. Patients with higher Bmi-1 expression had shorter sur-
vival time, and patients with lower Bmi-1 expression had
a longer survival time.
This study demonstrated that there was a significant dif-
ference in Bmi-1 expression at both protein and mRNA
levels between bladder cancer cells and the adjacent nor-
mal bladder tissue. Furthermore, Bmi-1 protein is up-reg-
ulated to a much greater extent than is Bmi-1 mRNA in
cancer tissue compared with non-cancerous tissues. This
observation suggests that dysregulation at the posttran-
scriptional level might be the major source of Bmi-1
expression in bladder cancers. Immunohistochemistry
demonstrated that bladder cancers showed moderate to
strong nuclear staining, while adjacent normal tissues
showed only weak Bmi-1 expression, or no Bmi-1 expres-
sion at all. These results were similar to those of previous
studies of other human cancers [14-18]. Furthermore,
intense expression of Bmi-1 in bladder cancer correlated
with its clinicopathologic features including tumor classi-
fication, recurrence, and TNM stage. Previous reports indi-
cated that the BMI1  gene may be a novel molecular
marker to predict the progression and prognosis of breast
cancer and myelodysplastic syndrome
(MDS)[19,20,23,24]. Consistent with previous reports of
other cancers, over-expression of Bmi-1 protein indicated
poor prognosis for patients with bladder cancer. The five-
year survival was significantly different between the two
groups, and the results showed that the greater the expres-
sion of Bmi-1 protein, the lower the survival rate.
The initiation and progression of bladder cancer involve a
series of genetic events including activation of oncogenes,
and the inactivation of tumor suppressors[6,25,26]. The
regulatory mechanism of the Polycomb group proteins
relies upon epigenetic modifications of specific histone
tails that are inherited through cell division[10,27].
Table 2: Overall survival analysis of different prognostic variable in patients with bladder cancer by Cox Regression Analysis
Univariate analysis Multivariate analysis
n P Hazard ratios (95% confidence interval) P Hazard ratios (95% confidence interval)
Clinical stage
Ta T1 83
T2 T3 T4 54
Histological grade




High 75 0.022 1.653(1.121–3.485) 0.032 1.863(1.132–3.753)
Low 62BMC Cancer 2009, 9:61 http://www.biomedcentral.com/1471-2407/9/61
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Because Bmi-1 is a member of the PcG family, Bmi-1 over-
expression could repress the p16Ink4a (CDKN2A) and
p19Arf targets[17,20]. In the absence of p16Ink4a, the
cyclin D/Cdk4/6 complex can phosphorylate pRB, allow-
ing the E2F-dependent transcription that leads to cell
cycle progression and DNA synthesis. Bmi-1-deficient
mouse embryonic fibroblasts (MEF) overexpress INK4a/
ARF locus-encoded genes CDKN2A and p19ARF (mouse
homologue of human p14ARF) and undergo premature
senescence in culture[28].
Conversely, overexpression of Bmi-1 reduces expression
of p16INK4a and p19ARF, and immortalizes MEFs[28].
Kang[29] found that Bmi-1 may act through a p16INK4A-
independent pathways to regulate cellular proliferation
during progression of oral cancer. In addition, MDM2-
mediated p53 degradation causes low p53 levels in the
absence of p19Arf, thus preventing cell cycle arrest and
apoptosis[30]. The BMI1 gene also can induce telomerase
activity to prevent apoptosis. Other investigators have
found that the frequent inactivation of the p14ARF and
CDKN2A genes may be an important mechanism for the
dysfunction of p53 and Rb growth regulatory pathways
during bladder cancer development [31-34]. However,
whether overexpression of BMI1 results in reduction of
p14ARF and CDKN2A gene expression requires further
investigation.
In our experience, the clinicopathologic features of blad-
der cancer are closely related to its prognosis. In our study,
we found that in addition to T classification and TNM
stage, Bmi-1 expression is an independent prognostic fac-
tor for bladder cancers. In the literature, the BMI1 gene is
reported to be related to the clinicopathologic features
and prognosis in other human cancers, including breast
cancer, colon cancer, and lung cancer [19-21]. Thus, we
believe that the BMI1 gene probably plays an important
role in cell proliferation and tumor progression in bladder
cancers. More studies are required to explore the relation-
ships between the BMI1 gene and other genes such as p14,
p16, and TP53, and its relationship to other molecules
that may be associated with bladder cancer.
Conclusion
This study demonstrated overexpression of Bmi-1 in blad-
der cancers. The overexpression of Bmi-1 protein was cor-
related with tumor classification, recurrence, clinical
stage, and prognosis. Greater expression of Bmi-1 protein
predicts a lower degree of differentiation, higher recur-
rence risk, and poorer prognosis. These results indicate
that the BMI1 gene may play an important role in the pro-
gression of bladder cancer; however, this study has several
limitations. In this study, the old WHO grading system
(grades 1, 2, and 3) was used, and lymphovascular inva-
sion was not recorded. In addition, we can say only that
Bmi-1 expression is an independent prognostic marker for
bladder cancer. It may offer new information that stage
and grade cannot provide, but more evidence is required
to support this conclusion. Prospective studies, additional
cases, and different antibodies would be required to test
the relationship between Bmi-1 expression and the clini-
cal biological behavior of bladder cancer.
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